<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3999</td>
<td>Highlights of This Issue</td>
<td></td>
</tr>
<tr>
<td>4001</td>
<td>CCR Translations</td>
<td>How to Develop Treatments for Biologically Heterogeneous &quot;Diseases&quot;&lt;br&gt;Richard M. Simon&lt;br&gt;&lt;br&gt;See article p. 4004</td>
</tr>
<tr>
<td>4004</td>
<td>Statistics in Clinical Cancer Research</td>
<td>Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819&lt;br&gt;Mary W. Redman, John J. Crowley, Roy S. Herbst, Fred R. Hirsch, and David R. Gandara&lt;br&gt;&lt;br&gt;See commentary p. 4001</td>
</tr>
<tr>
<td>4013</td>
<td>Molecular Pathways</td>
<td>Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia&lt;br&gt;Sarah E.M. Herman and Amy J. Johnson</td>
</tr>
<tr>
<td>4019</td>
<td>Molecular Pathways</td>
<td>Molecular Pathways: Involving Microenvironment Damage Responses in Cancer Therapy Resistance&lt;br&gt;Yu Sun and Peter S. Nelson</td>
</tr>
<tr>
<td>4026</td>
<td>HUMAN CANCER BIOLOGY</td>
<td>Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma&lt;br&gt;Katja Harbst, Johan Staaf, Martin Lauss, Anna Karlsson, Anna Másbäck, Iva Johansson, Pär-Ola Bendahl, Johan Vallon-Christersson, Therese Törnqvist, Henrik Ekedahl, Jürgen Geisler, Markus Höglund, Mattias Ringnér, Lotta Lundgren, Karin Jirstrom, Hakan Olsson, Christian Ingvar, Åke Borg, Hensin Tsao, and Göran Jonsson</td>
</tr>
<tr>
<td>4048</td>
<td>EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival&lt;br&gt;Michiel Smits, Sjoerd van Rijn, Esther Hulman, Dennis Biesmans, Dannis G. van Vuuren, Marcel Kool, Christine Haberler, Eleonora Aronica, W. Peter Vandertop, David P. Noske, and Thomas Würdinger</td>
<td></td>
</tr>
<tr>
<td>4059</td>
<td>Overexpression of GOLPH3 Promotes Proliferation and Tumorigenicity in Breast Cancer via Suppression of the FOXO1 Transcription Factor&lt;br&gt;Zhaolei Zeng, Huanxin Lin, Xiaohui Zhao, Guanglin Liu, Xi Wang, Ruihua Xu, Kun Chen, Jun Li, and Lihing Song</td>
<td></td>
</tr>
<tr>
<td>4070</td>
<td>CANCER THERAPY: PRECLINICAL</td>
<td>Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts&lt;br&gt;Gaspar J. Kitange, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Jenny L. Pokorny, Ling Cen, Paul A. Decker, Wenting Wu, Gwen A. Lomberk, Shiv K. Gupta, Raul A. Urrutia, and Jamn N. Sarkaria</td>
</tr>
<tr>
<td>4080</td>
<td>IGKV3 Proteins as Candidate &quot;Off-the-Shelf&quot; Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas&lt;br&gt;Debora Martorelli, Massimo Guidoboni, Valli De Re, Elena Muraro, Riccardo Turrini, Anna Merlo, Elisa Pasini, Laura Caggiari, Luca Romagnoli, Michele Spina, Roberta Mortarini, Daniela Gasparotto, Mario Mazzucato, Antonino Carbone, Antonio Rosato, Andrea Anichini, and Riccardo Dolcetti</td>
<td></td>
</tr>
</tbody>
</table>
The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel
Nadine Pasche, Sarah Wulhfard, Francesca Pretto, Elisa Carugati, and Dario Neri

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
Changgeng Qian, Cheng-Jung Lai, Rudi Bao, Da-Gong Wang, Jing Wang, Guang-Xin Xu, Ruzanna Atiyun, Hui Qu, Ling Yin, Maria Samson, Brian Zilicak, Anna Wai See Ma, Steven DellaRocca, Mylissa Berek, Hai-Xiao Zhai, Xiong Cai, and Maurizio Voi

Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma
Sun Joo Lee, Sukhen C. Ghosh, Hee Dong Han, Rebecca L. Stone, Justin Bottsford-Miller, De Yue Shen, Edmond J. Auzenne, Alejandro Lopez-Araujo, Chunhua Lu, Masato Nishimura, Chad V. Pecot, Behrouz Zand, Duangmani Thanapprapasr, Nicholas B Jennings, Yu Kang, Jie Huang, Wei Hu, Jim Klostersgaard, and Anil K. Sood

Progenitor-like Traits Contribute to Patient Survival and Prognosis in Oligodendrogial Tumors
Felicia Soo-Lee Ng, Tan Boon Toh, Esther Hui-Ling Ting, Geraldene Rong-Hui Koh, Edwin Sandanaraj, Mark Phong, Swee Seong Wong, Siew Hong Leong, Oi Lian Kon, Greg Tucker-Kellogg, Wai Hoe Ng, Ivan Ng, Carol Tang, and Beng Ti Ang

Breast Cancer Cell Targeting by Prenylation Inhibitors Elucidated in Living Animals with a Bioluminescence Reporter
Sharon L. Chinault, Julie L. Prior, Kevin M. Kaltenbronn, Anya Penly, Katherine N. Weilbaecher, David Piwnica-Worms, and Kendall J. Blumer

The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma
Yasumasa Miyazaki, Takeo Kosaka, Shuji Mikami, Eiji Kikuchi, Nobuyuki Tanaka, Takahiro Maeda, Masaru Ishida, Akira Miyajima, Ken Nakagawa, Yasunori Okada, Yasufumi Sato, and Mototsugu Oya

Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population
Nicolas Wentzensen, Lauren Schwartz, Rosemary E. Zuna, Katie Smith, Cara Mathews, Michael A. Gold, R. Andy Allen, Roy Zhang, S. Terence Dunn, Joan L. Walker, and Mark Schifferman

ERG Rearrangement for Predicting Subsequent Cancer Diagnosis in High-Grade Prostatic Intraepithelial Neoplasia and Lymph Node Metastasis
Xin Gao, Liao-Yuan Li, Fang-Jian Zhou, Ke-Ji Xie, Chun-Kui Shao, Zu-Lan Su, Qi-Peng Sun, Ming-Xun Chen, Jun Pang, Xiang-Yu Zhou, Jian-Guang Qiu, Xing-Qiao Wen, Ming Yang, Xian-Zhong Bai, Hao Zhang, Li Ling, and Zhong Chen

Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration
Ke Lin, Janet Adamson, Gillian G. Johnson, Anthony Carter, Melanie Oates, Rachel Wade, Sue Richards, David Gonzalez, Estella Matutes, Claire Dearden, David G. Oscier, Daniel Catovsky, and Andrew R. Pettitt

LETTERS TO THE EDITOR

Lifetime Cancer Risks of PTEN Mutation Carriers—Letter
Molly S. Daniels, Thereasa Rich, Scott Weissman, and Robert Pilarski

Lifetime Cancer Risks of PTEN Mutation Carriers—Response
Min-Han Tan, Jessica Mester, and Charis Eng

TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)
Lai Ling Cheng, Yoko Itahana, Zheng Deng Lei, Na-Yu Chia, Yonghui Wu, Yingnan Yu, Shun Li Zhang, Aye Aye Thike, Anuradha Pandey, Steve Rozen, Pieter Mathijs Voorhoeve, Qiang Yu, Puay Hoon Tan, Boom Huat Bay, Koji Itahana, and Patrick Tan

CORRECTIONS

Correction: New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy

Correction: MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer

ABOUT THE COVER

The recently discovered recurrent ERG rearrangement is highly specific for prostate cancer. There are significant associations of ERG rearrangement in preoperative biopsies with pelvic lymph node metastasis for patients with prostate cancer. The fluorescence in situ hybridization image shows representative nuclei of a prostate cancer gland. One yellow/one green/one red in a nucleus represents abnormal signal patterns indicative of an ERG rearrangement. For details, please see the article by Gao and colleagues on page 4163 of this issue.